Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to -$200,831.

  • Immuneering's Change in Accured Expenses fell 80.46% to $380,304 in Q4 2024 from the same period last year, while for Dec 2024 it was -$200,831, marking a year-over-year decrease of 127.82%. This contributed to the annual value of -$200,831 for FY2024, which is 127.82% down from last year.
  • Latest data reveals that Immuneering reported Change in Accured Expenses of -$200,831 as of FY2024, which was down 127.82% from $721,989 recorded in FY2023.
  • Immuneering's Change in Accured Expenses' 5-year high stood at $3.2 million during FY2021, with a 5-year trough of -$200,831 in FY2024.
  • Over the past 3 years, Immuneering's median Change in Accured Expenses value was $474,568 (recorded in 2022), while the average stood at $331,909.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 563.25% in 2021, then crashed by 127.82% in 2024.
  • Immuneering's Change in Accured Expenses (Yearly) stood at $488,644 in 2020, then soared by 563.25% to $3.2 million in 2021, then plummeted by 85.36% to $474,568 in 2022, then soared by 52.14% to $721,989 in 2023, then slumped by 127.82% to -$200,831 in 2024.